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Abstract
Background:  During carcinogenesis, tumors develop multiple mechanisms for evading the
immune response, including upregulation of Fas ligand (FasL/CD95L) expression. Expression of
FasL may help to maintain tumor cells in a state of immune privilege by inducing apoptosis of anti-
tumor immune effector cells. Recently this idea has been challenged by studies reporting that tumor
cells of varying origin do not express FasL. In the present study, we aimed to comprehensively
characterize FasL expression in tumors of both murine and human origin over a 72 hour time
period.
Methods: RNA and protein was extracted from six human (SW620, HT29, SW480, KM12SM,
HCT116, Jurkat) and three mouse (CMT93, CT26, B16F10) cancer cell lines at regular time
intervals over a 72 hour time period. FasL expression was detected at the mRNA level by RT-PCR,
using intron spanning primers, and at the protein level by Western Blotting and
immunofluorescence, using a polyclonal FasL- specific antibody.
Results: Expression of FasL mRNA and protein was observed in all cell lines analysed. However,
expression of FasL mRNA varied dramatically over time, with cells negative for FasL mRNA at many
time points. In contrast, 8 of the 9 cell lines constitutively expressed FasL protein. Thus, cells can
abundantly express FasL protein at times when FasL mRNA is absent.
Conclusion: These findings demonstrate the importance of complete analysis of FasL expression
by tumor cells in order to fully characterize its biological function and may help to resolve the
discrepancies present in the literature regarding FasL expression and tumor immune privilege.
Introduction
Recent advances in our understanding of the interactions
of tumor cells with the immune system has resulted in the
realisation that tumor cells devise multiple mechanisms
to evade recognition by immune cells. Upregulation of
Fas ligand (FasL/CD95L) expression may represent one
such mechanism [1]. FasL functions to induce apoptotic
cell death following ligation to its receptor Fas [2]. The
Fas/FasL system plays an important role in immune
homeostasis [3], and in the maintenance of immune priv-
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ilege in sites such as the eye [4] and testis [5]. For instance,
FasL expressed by non-lymphoid cells in the eye was
shown to induce apoptosis of Fas+ lymphoid cells entering
in response to viral infection, thus protecting the eye from
inflammatory damage. Following the discovery that
tumor cells can express FasL, it was subsequently sug-
gested that FasL may also confer immune suppression in
malignancy and that this may represent a critical mode of
tumor immune evasion – the 'Fas counterattack' [1,6,7].
However, this idea has recently been challenged [8]. Argu-
ments raised against the 'Fas counterattack' include stud-
ies showing that ectopic overexpression of FasL in
allografts of tissues or tumor cells leads in some cases to
inflammation and rapid rejection [9,10]. Also, the actual
ability of tumors to express FasL has been questioned,
with reports suggesting that tumor cells of varying origin
do not express FasL [11,12]. Furthermore, substantial con-
cerns have been raised about the specificity of some com-
mercially available anti-FasL antibodies [13].
In light of these concerns, the present study was designed
to investigate the expression of FasL at both the mRNA
and protein level, in cell lines of varying histological back-
grounds (colon carcinoma, melanoma and lymphoma),
and of both human and mouse origin. Expression of FasL
mRNA and protein was observed in all cell lines analysed.
However, while FasL expression varied over time at the
mRNA level (+/-), FasL was consistently detected at the
protein level throughout the culture period in eight of the
nine cell lines analysed using two different FasL-specific
antibodies. These results show that cells can abundantly
express FasL protein at time points when FasL mRNA is
absent and demonstrate the importance of complete anal-
ysis of FasL expression by tumor cells in order to fully
characterize its biological function.
Materials and methods
Cells
SW620, HT29 and SW480 human colon adenocarcinoma
cell lines and Jurkat T cell line were purchased from the
American Type Culture Collection (ATCC) (Rockville,
MD). The human colon carcinoma cell line, HCT116, was
a gift from Prof. B. Vogelstein (The John Hopkins Univer-
sity School of Medicine, Baltimore, MD). The human met-
astatic colon carcinoma cell line, KM12SM, was kindly
provided by Dr. Isaiah J Fidler (Department of Cancer
Biology, University of Texas, MD Anderson Cancer Cen-
tre). B16F10, a mouse melanoma cell line, CT26 and
CMT93, mouse colorectal carcinoma cell lines, were
kindly donated by Dr. Stephen Todryk (Oxford Univer-
sity, UK).
Cells were grown in DMEM unless otherwise stated.
KM12SM cells were grown in MEM supplemented with 2×
vitamins, 1 mM sodium pyruvate and 1× non-essential
amino acids. HCT116 were grown in McCoy's 5A. When
analysing FasL expression, cells were grown in medium
containing 100 U/ml penicillin, 100 µg/ml streptomycin,
0.5% fetal calf serum, 0.2% BSA, 10 µg/ml transferrin and
30 ηM sodium selenite.
Analysis of FasL expression
Each cell line was seeded individually at ~2 × 105 cells /ml
in 6 well plates. This was sufficient to achieve 20% conflu-
ency 18 hours later and this point was defined as 0 hour.
FasL expression was monitored thereafter by reverse tran-
scriptase-polymerase chain reaction (RT-PCR), Western
blotting and immunofluorescence at regular intervals over
the following 72 hours.
RT-PCR detection of FasL mRNA transcripts
The expression of FasL mRNA was analyzed by RT-PCR.
Total RNA was isolated using Tri Reagent (Molecular
Research Centre, Cincinnati, OH), according to the man-
ufacturer's instructions. 1.5 µg of total RNA was used for
first strand cDNA synthesis in a mixture containing AMV
Reverse Transcriptase, random hexanucleotide primers,
RNasin (40 U) and dNTPs (500 µM) (Promega, WI). Sub-
sequently, FasL cDNA was amplified by 35–40 cycles of
PCR using the following intron-spanning primers: human
FasL – forward 5'- GGATTGGGCCTGGGGATGTTTCA- 3'
and reverse 5'-TTGTGGCTCAGGGGCAGGTTGTTG-3'
(344 bp product); mouse FasL – forward 5'-CGGTGG-
TATTTTTCATGGTTCTGG-3' and reverse 5'-CTTGTGGTT-
TAGGGGCTGGTTGTT-3' (380 bp). To ensure comparable
amplification efficiencies in all RNA samples, β-actin RT-
PCR was also performed using the following primers: for-
ward 5'-CCTTCCTGGGCATGGAGTCCTG-3' and reverse
5'-GGAGCAATGATCTTGATCTT C-3' (202 bp). PCR prod-
ucts were resolved on a 2% agarose gel and visualized by
ethidium bromide staining.
Western blotting detection of FasL protein
Cells were rinsed once in PBS and lysed on ice for 5 mins
in 20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl and
1% triton × 100, supplemented with the complete-TM
mixture of protease inhibitors (Roche Molecular Bio-
chemicals, Indianapolis, IN). Lysates were sonicated and
cleared by micro centrifugation at 10,000 g for 5 mins.
Protein concentrations were determined using the BCA
protein assay (Pierce Chemicals, Rockford, IL). Equal
amounts of protein (50 µg for FasL; 15 µg for β-actin)
were separated in a 10% SDS polyacrylamide gel and
transferred to a nitrocellulose membrane. Protein loading
and efficiency of transfer were monitored by Ponceau S
staining. Membranes were blocked for 1 hour at room
temperature in Blotto (5% non-fat dry milk in 0.1% PBS/
Tween-20) and then incubated overnight at 4°C with 1
µg/ml rabbit polyclonal anti-FasL antibody (Ab-1; Onco-Journal of Carcinogenesis 2006, 5:5 http://www.carcinogenesis.com/content/5/1/5
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gene, CA), 0.1 µg/ml rabbit polyclonal anti-FasL antibody
(N-20; Santa Cruz, CA) or mouse monoclonal anti-β-actin
specific antibody (1:10,000) (Clone AC-74; Sigma, UK).
Primary antibodies were detected with horseradish perox-
idase-conjugated IgG (Dako Corp., Carpinteria, CA)
raised against the corresponding species followed by ECL
visualization (Pierce Chemicals).
Immunofluorescent detection of FasL in human and mouse 
cell lines
For immunostaining, slides were fixed with 1.5% parafor-
maldehyde and then blocked with 10 mg/ml BSA plus 1%
rabbit serum for 30 minutes at room temperature. Human
cell monolayers were incubated overnight at 4°C with 2
µg/ml anti-FasL specific antibody (G247-4; Pharmingen,
UK) while mouse cell monolayers were incubated with 20
µg/ml of monoclonal anti-FasL specific antibody (A11;
Alexis Biochemical, UK) for 1 hour at room temperature.
Antibody binding was localized using a FITC-labeled sec-
ondary antibody (Dako). Slides were mounted with anti-
fading media (Dako) and visualized using a fluorescent
microscope when dry.
Results
Cancer cell lines of varying origin express FasL mRNA and 
protein in a cyclic manner
Given the recent discrepancies in the literature regarding
FasL expression by various tumor cell lines, FasL mRNA
expression by six human tumor cell lines (one T-cell lym-
phoma and five colon carcinomas) was analysed by RT-
PCR. Expression was examined at three hour intervals
over a period of 72 hours. Intron spanning primers were
used to avoid amplification of contaminating genomic
DNA. The FasL mRNA transcript was detectable at numer-
ous time points throughout the 72 hour culture period
(Figure 1A). All cell lines investigated expressed FasL
mRNA; however, expression varied dramatically over
time, with cells negative for FasL mRNA at many time
points. Despite this cyclic pattern of expression, coupled
with very low levels of FasL mRNA for some cell lines (e.g.
Characterisation of FasL expression in tumor cell lines of human origin Figure 1
Characterisation of FasL expression in tumor cell lines of human origin. A: FasL mRNA expression by each cell line 
was analyzed at the indicated times by RT-PCR. β-actin RT-PCR was performed to monitor RT-PCR amplification efficiency, 
with all samples yielding equivalent levels. B: FasL protein expression was monitored by immunoblot analysis using the Ab-1 
anti-FasL antibody (Oncogene). Results are representative of three independent experiments.
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HCT116 colon carcinoma cells were positive for FasL
mRNA at only 3 of the 13 time points examined (3, 27
and 60 hours)), all cells were observed to constitutively
express FasL protein as assessed by Western blotting (Fig-
ure 1B).
To determine whether this phenomenon was conserved
across different species, FasL expression was also analysed
in three tumor cell lines of murine origin (two colon car-
cinoma and one melanoma) (Figure 2A). Again expres-
sion varied dramatically over time. In fact, B16F10
melanoma cells expressed FasL mRNA at just a single time
point (6 hours). Despite this, Western blot analysis
revealed constitutive FasL protein expression (Figure 2B).
In contrast, CT26 colon carcinoma cells expressed FasL
mRNA at 5 of the 13 time points, yet FasL protein was not
detected following 12 and 24 hours in culture.
Additional confirmation of the lack of correlation
between FasL mRNA and protein expression was provided
by immunofluorescent staining (Figure 2C). At 48 hours,
B16F10 and CMT93 cells expressed comparable levels of
FasL protein, yet both of these cell lines fail to express FasL
mRNA at this time. Moreover, CMT93 cells overall express
substantially higher levels of FasL mRNA than B16F10
cells.
Confirmation of antibody specificity
Another argument levelled against the 'Fas counterattack'
as a mechanism of tumor immune evasion relates to the
specificity of some commercially available antibodies. For
this reason, in our study we used two different non-con-
tested antibodies (Ab-I, Oncogene; N-20, Santa Cruz) for
Western blotting. Both antibodies demonstrated a similar
pattern of FasL expression (Figure 3A). The specificity of
the antibodies was further validated by activating Jurkat T
cells using phytohemagglutinin (PHA). In vitro, T cell acti-
vation leads to increased expression of FasL. PHA-acti-
vated Jurkat T cells exhibited substantially increased levels
of FasL protein (Figure 3B). Also, increased expression of
FasL was detected in SW620 and SW480 cells following
treatment with matrix metalloproteinase (MMP) inhibi-
Analysis of FasL expression in murine tumor cell lines Figure 2
Analysis of FasL expression in murine tumor cell lines. A. FasL expression by murine tumor cells was analyzed by RT-
PCR at the indicated times. B. FasL protein expression was monitored by Western blotting using the Ab-1 anti-FasL antibody. 
C. After 48 hrs culture, FasL expression was detected by immunofluorescence on paraformaldehyde-fixed cell monolayers. 
Representative cell lines are shown – (a) EL-4 (murine T-cell line – positive control), (b) CMT93 and (c) B16F10. Results are 
representative of three independent experiments.
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tors (Figure 3B). MMP inhibitors prevent the cleavage of
FasL from the surface of the cells, leading to increased lev-
els of membrane-bound FasL.
The cyclic nature of FasL expression is not due to the 
degree of confluency of the cells or cellular stress in vitro
Several parameters may regulate the expression of FasL in
vitro, including confluency, serum deprivation, growth
factor withdrawal and cellular stress [14,15]. To minimise
the effect of these factors, all tumor-derived cell lines were
grown in serum-supplemented media containing essen-
tial nutrients. Cells were plated at ~20% confluency and
after 72 hours in culture were viable and exhibited ~80–
90% confluency (Figure 4). Consequently, the cyclic
nature of FasL expression observed in this report was not
due either to the cells becoming over-confluent or to cel-
lular stress. In fact, six of the nine cell lines exhibited
reduced or negligible levels of FasL mRNA at 72 hours.
Discussion
The role of FasL in tumor immune evasion and immune
privilege is controversial [8,16]. Arguments leveled
against a role for FasL include the failure of some investi-
gators to detect FasL expression by tumor cells, together
with the lack of specificity exhibited by some commer-
cially available antibodies. In the present study, we char-
acterized FasL expression by nine different tumor cell lines
of varying origin. We found that cells can maintain consti-
tutive FasL protein expression, despite extensive variations
in, and at times absent, FasL mRNA production.
These findings provide a rational explanation for some of
the conflicting reports present in the literature regarding
FasL expression. For instance, Rudi and colleagues dem-
onstrated the presence of FasL mRNA in 2 gastric carci-
noma cell lines, including Kato III cells [17]. However,
Tinhofer et al. were unable to detect FasL mRNA in this
cell line [12]. Also, Hahne et al. reported that melanoma
cells, including B16F10 cells [18], express FasL, while
Chappell et al. were unable to detect FasL mRNA in a
panel of early passage melanoma cell lines [11]. In all of
these reports, FasL mRNA expression was analysed at a
single time. The results of the current study clearly show
that analysis at a single time point is insufficient to con-
clude the presence or absence of FasL expression. Depend-
ing on the time at which the cells are analysed, tumors
Confirmation of the specificity of FasL protein detection Figure 3
Confirmation of the specificity of FasL protein detection. A. FasL protein was detected by Western blotting using both 
the Ab-1 and N-20 anti-FasL antibodies. Results from three representative cell lines are shown. B. FasL protein production was 
also detected by Western blotting using the Ab-1 antibody following PHA activation of Jurkat cells and treatment of SW620 
and SW480 cells with MMP inhibitors. Results are representative of three independent experiments.
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CT26 cell morphology during the course of FasL 
analysis. Cell lines were seeded at ~2 × 105 cells/ml in 6 well 
plates to achieve 20% confluency 18 hours later. This point 
was defined as 0 hr. After 72 hrs, cells had reached ~80–90% 
confluency.
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may or may not express FasL mRNA. These findings cau-
tion against relying on a single time point when analysing
the expression of mRNA, and emphasize the importance
of confirming any findings at the protein level.
Much of the controversy surrounding the 'Fas counterat-
tack' as a mechanism of tumor immune evasion stems
from transplantation studies. As a mediator of immune
privilege, it was hoped that FasL could be used to prevent
rejection of allografts. However, forced, overexpression of
FasL in allografts or tumor cells induced accelerated
destruction in many instances via recruitment of neu-
trophils [9,10,19]. Many rodent transplantation studies
have utilised CT26 colon tumor cells, which they reported
to be negative for FasL expression [9,19]. However, exten-
sive characterisation of this cell line in the current study
revealed that these cells do express FasL, albeit in a cyclic
fashion, at both the mRNA and protein level. Thus, trans-
fection of these FasL-expressing cells with recombinant
FasL may result in an excessive level of expression of FasL
by these cells. Indeed, downregulation of FasL expression
was recently shown to result in an increased anti-tumor
immune challenge and decreased tumor formation in vivo,
providing functional evidence in favor of the 'Fas counter-
attack' as a mechanism of tumour immune evasion [20].
The level of FasL expression has been shown to be impor-
tant in mediating immune privilege [21,22], with exces-
sive levels of FasL being linked to inflammation, perhaps
due to excessive apoptosis in the vicinity of the allograft
[23]. However, selective pressure during the gradual evo-
lution of a spontaneous tumor would ensure that FasL
upregulation could only occur at a level where it would be
advantageous to the tumor. Furthermore, to date, natu-
rally expressed FasL has not been shown to possess a
potent pro-inflammatory activity and is instead associated
with immunosuppressive and anti-inflammatory effects.
Recent publications have suggested that pre-formed FasL
can be stored in microvesicles, which can traffic to the cell
surface and induce apoptosis of Fas-bearing sensitive cells
[24,25]. Thus, the ability of FasL-expressing cells to trigger
apoptosis may not depend on de novo protein synthesis.
Instead, FasL protein may be present in a cell, in the
absence of FasL mRNA. These findings are consistent with
those of the current study and suggest that FasL may be
regulated at the transcriptional level. Following the syn-
thesis of sufficient amounts of FasL protein, the level of
FasL mRNA may decline, perhaps to prevent the transla-
tion of excessive amounts of FasL protein which could
potentially trigger neutrophil recruitment. Cyclic varia-
tion in the expression of FasL was seen in cells of both
mouse and human origin, suggesting that this represents
an important means of regulating FasL production for
cells.
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